FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials

Dominic Kaddu-Mulindwa1, Bettina Altmann2, Gerhard Held1, Stephanie Angel1, Stephan Stilgenbauer1, Lorenz Thurner1, Moritz Bewarder1, Maren Schwier1, Michael Pfreundschuh1, Markus Löfler2, Karin Menhart3, Jirka Grosse3, Marita Ziepert2, Ken Herrmann4, Ulrich Dührsen5, Andreas Hüttmann5, Francesco Barbato4, Viola Poeschel1, Dirk Hellwig3

Received: 3 January 2021 / Accepted: 29 March 2021 / Published online: 29 April 2021 © The Author(s) 2021

Abstract

Purpose Fluorine-18 fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG PET/CT) is the standard for staging aggressive non-Hodgkin lymphoma (NHL). Limited data from prospective studies is available to determine whether initial staging by FDG PET/CT provides treatment-relevant information of bone marrow (BM) involvement (BMI) and thus could spare BM biopsy (BMB).

Methods Patients from PETAL (NCT00554164) and OPTIMAL>60 (NCT01478542) with aggressive B-cell NHL initially staged by FDG PET/CT and BMB were included in this pooled analysis. The reference standard to confirm BMI included a positive BMB and/or FDG PET/CT confirmed by targeted biopsy, complementary imaging (CT or magnetic resonance imaging), or concurrent disappearance of focal FDG-avid BM lesions with other lymphoma manifestations during immunochemotherapy.

Results Among 930 patients, BMI was detected by BMB in 85 (prevalence 9%) and by FDG PET/CT in 185 (20%) cases, for a total of 221 cases (24%). All 185 PET-positive cases were true positive, and 709 of 745 PET-negative cases were true negative. For BMB and FDG PET/CT, sensitivity was 38% (95% confidence interval [CI]: 32–45%) and 84% (CI: 78–88%), specificity 100% (CI: 99–100%) and 100% (CI: 99–100%), positive predictive value 100% (CI: 96–100%) and 100% (CI: 98–100%), and negative predictive value 84% (CI: 81–86%) and 95% (CI: 93–97%), respectively. In all of the 36 PET-negative cases with confirmed BMI patients had other adverse factors according to IPI that precluded a change of standard treatment. Thus, the BMB would not have influenced the patient management.

Conclusion In patients with aggressive B-cell NHL, routine BMB provides no critical staging information compared to FDG PET/CT and could therefore be omitted.

Trial registration NCT00554164 and NCT01478542

Keywords FDG PET/CT · Lymphoma · Aggressive B-cell lymphoma · Bone marrow biopsy · Diagnostic performance

Dominic Kaddu-Mulindwa, B. Altmann, V. Poeschel and D. Hellwig contributed equally to this work.

Michael Pfreundschuh is deceased.

This article is part of the Topical Collection on Hematology

1 Department of Hematology, Oncology, Clinical Immunology, Rheumatology, Medical School, University of Saarland, Kirberger Str. 100, 66421 Homburg, Germany
2 Institute for Medical Informatics, Statistics and Epidemiology, University Leipzig, Leipzig, Germany
3 Department of Nuclear Medicine, University Hospital Regensburg, Regensburg, Germany
4 Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany
5 Department of Hematology, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany

Springer
Background

Non-Hodgkin lymphoma (NHL) is responsible for about 6% of all cancer deaths in the western world [1]. Diffuse large B-cell lymphoma (DLBCL) is the most common subgroup accounting for 30–58% of lymphoma patients [2, 3]. Bone marrow involvement (BMI) may influence prognosis and treatment of aggressive B-cell NHL. The addition of the anti-CD20 antibody rituximab to CHOP polychemotherapy (doxorubicin, cyclophosphamide, vincristine, prednisone) has significantly improved the outcome of patients with DLBCL [4, 5]. The International Prognostic Index (IPI) can predict prognosis [6, 7]. An essential part of the IPI is the clinical stage, and BMI is classified as stage IV [8], indicating a less favorable prognosis. The recently published FLYER study demonstrated that the number of chemotherapy cycles can be reduced in patients younger than 60 years with low-risk IPI [9]. Taken together, the initial determination of the clinical stage including BMI remains crucial for treatment decisions and prognosis.

Study results show that, due to its higher sensitivity and specificity, fluorine-18 fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG PET/CT) is superior to computed tomography (CT) alone in the detection of lymphoma manifestations [10]. It is therefore recommended for staging [11].

For decades, bone marrow biopsy (BMB) has been the standard for the evaluation of BMI in lymphoma. Evidence has been presented that BMI may also be detected by FDG PET/CT in patients with aggressive B-cell NHL. According to a recent meta-analysis, FDG PET/CT detects initial BMI with higher sensitivity than BMB, suggesting that BMB may be dispensable [12]. The meta-analysis included a total of 654 patients from 7 studies (2 prospective, 3 retrospective, 2 with unreported design) with up to 133 cases and a maximum of 55 patients in a prospective study [12]. In a pooled estimator, the sensitivity and specificity of FDG PET/CT for BMI were 88.7% (CI: 82.5–93.3%) and 99.8% (CI: 98.8–100%), respectively [12]. More recent prospective studies with concordant results addressed the performance of FDG PET/CT compared to BMB for staging and BMI in mixed populations of 68 patients with FDG-avid lymphoma including 16 DLBCLs [13] or 35 patients with aggressive NHL, respectively [14]. To the best of our knowledge, there is no large prospective study on the performance of FDG PET/CT in comparison to BMB for the detection of BMI in aggressive B-cell NHL.

Our aim was to analyze the diagnostic performance and relevance of FDG PET/CT for initial staging regarding BMI in aggressive B-cell NHL using data from two large prospective randomized multicenter trials of high methodological quality. We set out to answer the question whether noninvasive FDG PET/CT can diagnose BMI more reliably than invasive BMB does, rendering the latter dispensable.

Methods

The present analysis was requested by the German Joint Federal Committee (Gemeinsamer Bundesausschuss, G-BA), the highest council of collective self-government of the German healthcare system under supervision of the German Federal Ministry of Health. The investigation used the data from two German prospective phase 3 trials: the PETAL study (NCT00554164) [15] and the OPTIMAL>60 study (NCT01478542). The first investigated whether FDG PET/CT can guide therapy in patients with aggressive NHL, whereas the second is an ongoing randomized trial including elderly patients with aggressive B-cell NHL with the purpose of improving outcome and reducing toxicity by using an optimized schedule of rituximab, substituting conventional by liposomal vincristine, and PET-guided reduction of therapy. The results presented here do not represent endpoints of the studies and have no influence on the endpoints or the conduct of the ongoing OPTIMAL>60 trial. According to the trial protocols, both a BMB and an FDG PET/CT were performed during initial staging. Patients were excluded from the analysis if a diagnosis of aggressive B-cell lymphoma could not be confirmed by reference pathology, if BMB or FDG PET/CT were not done, or if the BMB or imaging data were unavailable for central review. In order to ensure comparability of the patient cohorts, only patients with a biopsy-proven, centrally confirmed diagnosis of DLBCL, primary mediastinal B-cell lymphoma (PMBCL), or follicular lymphoma grade 3b (FL3b) were included (Fig. 1).

Central reading of PET/CT

All FDG PET/CT images were centrally reviewed for BMI by an one expert from a panel of nuclear medicine physicians (DH, JG, KM, FB, KH) with board certifications for CT (DH, JG, KM) and MRI (DH) who were blinded to the results of BMB. PET/CT images were obtained as pseudonymized DICOM data sets from the study centers. PET/CT images were visualized as reported in the Supplemental Materials.

PET criteria for BMI

The distribution pattern of FDG uptake in BM was rated as normal, diffusely increased, or unifocal/multifocal. PET positivity was assessed visually and required an FDG uptake level above that in normal liver. Diffuse uptake (“uniform increased FDG uptake throughout the bone marrow space” [16]), without focal uptake, was considered negative for BMI; otherwise, it was considered positive. Namely, diffusely increased focal uptake and areas of asymmetric diffuse uptake were considered involved. Foci attributable to physiologic conditions (e.g., rib fractures or sites of previous BMB) were considered negative.
**Study-related evaluation of FDG uptake in BM and of osseous involvement**

For semiquantitative assessment in the present analysis, the intensity of FDG uptake in BM or in BM foci was rated by a 5-point scale in relation to mediastinal blood pool (MBP) and liver (1: no uptake, 2: less than or equal to MBP, 3: less than or equal to the liver, 4: moderately above the liver, 5: markedly above the liver) [10]. The anatomic localization of foci in the BM with increased FDG uptake was documented for further comparison. Osseous involvement was defined by an affection of the bone detected by CT as a lytic lesion or by MRI as a bone-invading lesion in cortical bone or in the cancellous bone (spongiosa) at the site of FDG uptake. If there was no anatomic imaging (full-dose CT, low-dose CT, or MRI) of adequate quality available for comparison in suspicious bone lesions, the presence of bone involvement was classified as “unknown” for these foci.

**Comparison of PET/CT and BMB findings**

In a first step, discordant cases of BMB and blinded central PET/CT reading were identified. Discordant findings were documented and resolved after unblinding by re-evaluation in consensus with at least one further panel member and interdisciplinary discussion using findings of complementary imaging and/or subsequent PET/CT examinations, if available. In case of an FDG PET/CT result positive for BMI with negative BMB, all available additional imaging data (mainly CT or targeted magnetic resonance imaging, MRI) and/or FDG PET/CT image data sets from restaging or follow-up examinations were used to determine the final diagnosis of BMI.

**Definition of BM involvement**

Based on the published criteria of Berthet and coworkers [17], a newly defined gold standard was used as reference standard for BMI. It included a positive BMB, a positive FDG PET/CT in discordant cases confirmed by targeted biopsy or complementary CT imaging (if available CT series from PET/CT were nondiagnostic, e.g., due to limitations from low-dose CT protocols), or targeted MRI or concurrent disappearance of focal FDG PET-avid lesions in the BM together with other lymphoma manifestations after immunochemotherapy.

Identification of bone marrow infiltration was done using unilateral iliac crest biopsy. Marrow biopsy specimens were reported by a reference hematopathologist. The presence of lymphoma was based on standard immunohistochemistry, including antibodies to identify CD3-, CD79a-, and CD20-positive cells.
**Statistical analysis**

To investigate whether the subgroups analyzed in this study were representative of the total trial populations, characteristics of included and excluded patients were compared using the chi², Fisher exact, and Wilcoxon rank sum tests. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated with 95% confidence intervals (CI) to assess the diagnostic performance of FDG PET/CT and BMB in relation to the newly defined gold standard. For the comparison of sensitivities, the McNemar test was used [18]. Statistical evaluation was performed using SPSS Statistics 25 software (SPSS, Chicago, IL). The 95% Clopper-Pearson CIs were determined in Cytel Studio 8.0.

**Results**

**Patient characteristics**

From the PETAL and the OPTIMAL>60 trials, subgroups of 660 and 825 patients, respectively, with histopathologically confirmed aggressive B-cell NHL of the subtypes DLBCL, PMBCL, and FL3b, were eligible for this pooled analysis. In 433 and 504 cases, both PET/CT images and BMB reports were available and suitable for analysis in 427 and 503 patients, respectively (Fig. 1). Characteristics were similar in patients included and excluded from this analysis (Supplemental Table 1).

The demographic and clinical characteristics of the analysis population are shown in Table 1. Overall, both cohorts (PETAL and OPTIMAL>60) had similar characteristics, except for age, which was due to the inclusion criteria of the trials (the PETAL study included patients 18–80 years of age; the OPTIMAL>60 study only includes patients aged 61–80 years). The median age of all analyzed patients was 68 years, 56% were male, and 54% had an advanced stage. According to BMB, 36 of the 427 patients from PETAL (8%) and 49 of the 503 patients from OPTIMAL>60 (10%) had BMI; thus, BMB confirmed BMI in 85 of 930 patients in total (9%). According to initial FDG PET/CT, 88 of the 427 patients from PETAL (21%) and 97 of the 503 patients from OPTIMAL>60 (10%) had BMI; thus, BMB confirmed BMI in 85 of 930 patients in total (9%). According to initial FDG PET/CT, 88 of the 427 patients from PETAL (21%) and 97 of the 503 patients from OPTIMAL>60 (10%) had BMI; thus, BMB confirmed BMI in 85 of 930 patients in total (9%). According to initial FDG PET/CT, 88 of the 427 patients from PETAL (21%) and 97 of the 503 patients from OPTIMAL>60 (10%) had BMI; thus, BMB confirmed BMI in 85 of 930 patients in total (9%).

**Comparison of initial FDG PET/CT and BMB**

Of the 930 patients analyzed, 709 (76%) had a negative baseline FDG PET/CT and a negative BMB, whereas 49 (5%) had a positive FDG PET/CT and a negative BMB as demonstrated in Fig. 2. Thirty-six patients (4%) had a discordant result with FDG PET/CT negative for BMI but positive BMB. Among these 36 patients, 17 (47%, 3 in PETAL, 14 in OPTIMAL>60) had an indolent (discordant) NHL in the BMB, whereas the other 19 patients had an aggressive (concordant) B-cell lymphoma. One hundred thirty-six patients (15%) had a discordant result with a positive FDG PET/CT and a negative BMB (Table 2).

**Re-evaluation of discordant findings with imaging**

Differences between BMB and FDG PET/CT were further reviewed by the expert panel. In the OPTIMAL>60 study, re-evaluation included further imaging (CT, MRI) and FDG PET/CT follow-up examinations. In 69 of the 74 cases with positive FDG PET/CT and negative BMB, FDG uptake completely or partially disappeared in the course of therapy, compatible with initial BMI. Figure 3 illustrates a typical case. The 5 remaining patients had no FDG PET/CT follow-up scans. They had unifocal (n = 2) or multifocal (n = 3) FDG uptake in the BM with involvement of the humerus, femur, and digits. According to CT criteria, these lesions were classified as BMI. Thus, all 74 patients with positive FDG PET/CT and negative BMI had convincing evidence of true BMI, which, however, remained undetected by BMB (Supplemental Table 2). The 62 discordant cases of the PETAL could not be further evaluated, because FDG PET/CT follow-up scans and/or additional imaging procedures were not available.

**Final diagnosis of BMI**

The reference standard for BMI resulted in 709 cases that were negative, and 221 cases that were positive for BMI, with a prevalence of BMI of 221/930 = 24%.

**Diagnostic performance of BMB for the detection of BMI**

Since 709 of the 845 BMB-negative cases were also negative according to the reference standard, the NPV of BMB was 84% (CI: 81–86%) (Table 3). The sensitivity of BMB was 38% (CI: 32–45%), since 85 of 221 cases...
diagnosed by the reference standard were also identified by BMB. All 85 BMB-positive cases were also positive by the reference standard, so the PPV was 100% (CI: 96–100%). The specificity was also 100% (CI: 99–100%) (Table 3).

### Diagnostic performance of FDG PET/CT for the detection of BMI

As compared to the reference standard, 185 of 221 cases with BMI were detected by FDG PET/CT (Table 3), resulting in a
sensitivity of 84% (CI: 78–88%). On the other hand, 709 of the 745 reference standard-negative cases were also found to be negative by FDG PET/CT, resulting in a NPV of 95% (CI: 93–97%). All 185 PET-positive cases were confirmed to represent BMI by central review, resulting in a PPV of 100% (CI: 98–100%). Of the 709 PET-negative findings, all were confirmed to be negative, so the specificity was 100% (CI: 99–100%).

The sensitivity of FDG PET/CT was significantly higher than that of BMB (84% versus 38%; \( p < 0.001 \)).

**Effect of BMI detection on stage**

Lactate dehydrogenase (LDH) levels were increased above the upper limit of normal in 26 of the 36 BMI cases that were missed by FDG PET/CT. From the remaining 10 patients, one had an ECOG performance status > 1 and 9 were in stage III/IV. Thus, every single patient whose BMI was missed by FDG PET/CT had another adverse characteristic according to IPI precluding eligibility for reduced chemotherapy [9].

On the other side, we observed that in 136 patients with an FDG PET/CT positive for BMI but negative BMB, a portion of 80% was already in stage III/IV according to CT-based Ann Arbor staging. Therefore, 27 patients (BMB negative but FDG PET/CT positive for BMI) would be upstaged (from stage I/II to stage III/IV) by FDG PET/CT.

**Discussion**

The current analysis is derived from a comprehensive data set which originates from two large prospective randomized multicenter phase 3 trials. To our knowledge, with 930 analyzed patients, this is the largest cohort from prospective studies for the comparison of FDG PET/CT and BMB to detect BMI. In comparison, Alzahrani et al. analyzed the value of routine BMB in 530 patients with DLBCL showing no additional diagnostic or prognostic value of BMB over PET/CT alone. In contrast to our analysis, their study was retrospective which may have led to a selection bias [19]. Due to the size and inclusion criteria of our trials, the risk of a significant selection bias appeared small. Both the PETAL and the OPTIMAL>60 trials included patients with aggressive B-cell NHL irrespective of stage or IPI risk group.

Based on BMB, DLBCL involves the BM in up to 27% of cases [20–22]. The prognostic impact of BMI varies according to the degree and type (concordant versus discordant) of infiltration [22]. In our analysis, the prevalence of BMI detected by BMB was only 9% (85 of 930 patients), reflecting low sensitivity (in our analysis only 38%). Our observation is consistent with recently published data [23]. In 74 patients treated in the OPTIMAL>60 trial, BMB performed on the iliac crest did not detect BMI, mainly because the involvement was focal rather than general. Focal involvement has previously been demonstrated in studies comparing bilateral versus unilateral BMB [24]. Taking FDG PET/CT and BMB together, 221 of 930 patients showed BMI leading to a prevalence of 24% which is in line with the observed frequency in other studies [16, 17, 19, 25, 26]. In our analysis, the PPV for FDG PET/CT compared to the reference standard was 100% (CI: 98–100%). Therefore, BMB is dispensable if BMI is detected by FDG PET/CT.

One may ask how many of the patients with diffuse FDG uptake in BM above that in the liver had BMI. We can analyze this most accurately by looking at the data from the OPTIMAL>60 subpopulation where 26 patients exhibited...
diffuse FDG uptake in BM above that in the liver. In four (1 with moderately and 3 with markedly increased uptake), the PET pattern of inhomogeneous or asymmetric FDG uptake into the BM was interpreted (and confirmed) as BMI. PET was interpreted as negative for BMI in 22 patients with diffuse FDG uptake in BM (19 moderately and 3 markedly above the liver) with 6 false-negative cases (all with FDG uptake in BM only moderately above that in the liver). Thus, 10 of 26 patients (38%) with diffuse uptake above the liver had BMI (3 of 6 (50%) with markedly increased BM uptake and 7 of 20 (35%) with moderate uptake). Considering all false-negative BM PET results in the OPTIMAL>60 subpopulation, the pattern of FDG uptake was regarded as normal in 20 patients (1 with uptake less or equal to mediastinal blood pool, 12 with uptake less or equal to the liver, and 7 cases with FDG uptake in BM only moderately above that in the liver), while in 6 patients, it was diffusely increased but with a uniform appearance (all only moderately above the level of the liver). In most,

**Fig. 3** Female patient with diffuse large B-cell lymphoma and multifocal bone marrow involvement at baseline FDG PET/CT (INI), which was missed by bone marrow biopsy and remitted completely after 6 cycles of chemoimmunotherapy (RE2). Maximum-intensity projections in frontal and lateral view.

|              | PETAL | OPTIMAL>60 | Total |
|--------------|-------|------------|-------|
| **BMB**      |       |            |       |
| Negative     | 329 (77%) | 380 (76%)  | 709 (76%) |
| Negative     | 62 (15%)  | 74 (15%)   | 136 (15%) |
| Positive     | 10 (2%)   | 26 (5%)    | 36 (4%)   |
| Positive     | 26 (6%)   | 23 (5%)    | 49 (5%)   |
| **FDG PET/CT** | Reference standard |       |       |
| Negative     | 329 (77%) | 380 (76%)  | 709 (76%) |
| Negative     | 62 (15%)  | 74 (15%)   | 136 (15%) |
| Positive     | 0 (0%)    | 0 (0%)     | 0 (0%)    |
| Positive     | 36 (8%)   | 49 (10%)   | 85 (9%)   |

**Table 2** Comparison of the bone marrow biopsy results, the baseline FDG PET/CT results, and the newly defined gold standard regarding bone marrow involvement, respectively.

Abbreviations: BMB, bone marrow biopsy; FDG PET/CT, fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography.
of adverse events such as infection or bleeding [29].

More painful than a PET/CT is, and it is associated with the risk resulting from these procedures. But without doubt, a BMB is sets, there was no information available about adverse events PET/CT as pre-trial examinations were not recorded in our data result is influenced by the presence or absence of BMI [28].

Importantly, BMB is an invasive procedure whereas FDG PET/CT is noninvasive. Since side effects of BMB or FDG PET/CT as pre-trial examinations were not recorded in our data sets, there was no information available about adverse events resulting from these procedures. But without doubt, a BMB is more painful than a PET/CT is, and it is associated with the risk of adverse events such as infection or bleeding [29].

Berthet et al. proposed criteria to confirm BMI in cases exclusively diagnosed by FDG PET/CT [17]. As compared to the previous definition, the criteria used here also included the information obtained from targeted CT imaging (not only MRI) which is more commonly available than MRI.

The newly defined “gold” standard may have limitations. The specificity of FDG PET/CT may be limited due to potential FDG uptake in benign bone lesions [30] even though additional full-dose CT or MRI might help to characterize such lesions. Nevertheless, PET/CT in our analysis had a specificity of 100% with no false-positive findings. Diagnostic performance is improved as shown by the clarification of discordant findings by complementary imaging. We cannot exclude false-negative findings when both BMB and FDG PET/CT fail to demonstrate BMI. Whole-body MRI might provide similar sensitivity as FDG PET/CT for BMI, but this has only been prospectively evaluated in a limited number of aggressive NHL patients [14].

The prognostic value of BMI as detected by FDG PET/CT would be of interest. However, outcome data from the OPTIMAL>60 trial are not yet available, because it is an ongoing study.

Our analysis has some limitations, as it includes individual patient data from trials with different inclusion criteria. Most important are the differences in patient age since OPTIMAL>60 includes only patients aged 61 years and above. However, even with different inclusion criteria, no significant differences were observed between the studies in the incidence of BMI or other findings underlining the strength of our analysis.

In summary, baseline FDG PET/CT more accurately detects BMI than BMB, with considerably higher sensitivity of 84% versus 38%. By using FDG PET/CT, BMB can be omitted in the vast majority of patients with aggressive NHL. Our results lend further support to clinical practice guidelines recommending replacement of BMB by FDG PET/CT in the initial staging of DLBCL [11, 31].

Table 3 Diagnostic test parameters with 95% confidence intervals of the bone marrow biopsy and baseline FDG PET/CT results in comparison to the newly defined gold standard regarding bone marrow involvement, respectively

|                | PETAL n=427 | OPTIMAL>60 n=503 | Total n=930 |
|----------------|-------------|------------------|-------------|
| **BMB versus reference standard** |             |                  |             |
| Sensitivity    | 36/98 (37%) | (27%; 47%)       | 49/123 (40%) | (31%; 49%) | 85/221 (38%) | (32%; 45%) |
| Specificity    | 329/329 (100%) | (99%; 100%)   | 380/380 (100%) | (99%; 100%) | 709/709 (100%) | (99%; 100%) |
| Positive predictive value | 36/36 (100%) | (90%; 100%)       | 49/49 (100%) | (93%; 100%) | 85/85 (100%) | (96%; 100%) |
| Negative predictive value | 329/391 (84%) | (80%; 88%)       | 380/454 (84%) | (80%; 87%) | 709/845 (84%) | (81%; 86%) |
| **FDG PET/CT versus reference standard** |             |                  |             |
| Sensitivity    | 88/98 (90%) | (82%; 95%)       | 97/123 (79%) | (71%; 86%) | 185/221 (84%) | (78%; 88%) |
| Specificity    | 329/329 (100%) | (99%; 100%)   | 380/380 (100%) | (99%; 100%) | 709/709 (100%) | (99%; 100%) |
| Positive predictive value | 88/88 (100%) | (96%; 100%)       | 97/97 (100%) | (96%; 100%) | 185/185 (100%) | (98%; 100%) |
| Negative predictive value | 329/339 (97%) | (95%; 99%)       | 380/406 (94%) | (91%; 96%) | 709/745 (95%) | (93%; 97%) |

Abbreviations: BMB, bone marrow biopsy; FDG PET/CT, fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography; OPTIMAL, prospective open-label study; NCT, number of clinical trials.
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00259-021-05348-6.

Acknowledgements The authors are grateful to all patients and their relatives as well as to the participating investigators and subinvestigators of the PETAL and OPTIMAL>60 trials for their continued support. We would like to thank Beate Mann and Katja Rillich (IMISE Leipzig) for technical assistance.

Author contribution D.KM., V.P., G.H., S.A., S.S., L.T., M.B., M.S., M.P., M.L., K.M., J.G., K.H., U.D., A.H., F.B., B.A., M.Z., and D.H. contributed to the collection, review, and/or analysis of the data; B.A. and M.Z. performed statistical analysis of the data; D.KM., B.A., G.H., V.P., U.D., and D.H. wrote the manuscript.

Funding Open Access funding enabled and organized by Projekt DEAL. This work was supported by Deutsche Krebshilfe (grant nos. 107592 and 110515 to Ulrich Dührsen), Amgen GmbH Germany, and Roche Pharma (institutional research funding to the University Hospital Essen) for the PETAL study. The OPTIMAL>60 study is financially supported by Acrotech Biopharma LLC, F. Hoffmann La Roche Ltd., and Amgen GmbH Germany. Data collection, data analysis, and interpretation of data, writing of the paper, and decision to submit were left to the authors’ discretion and were not influenced. The present analysis was initiated and funded by the German Joint Federal Committee (Gemeinsamer Bundesausschuss, G-BA).

Declarations

Ethics approval and consent to participate Both trials were approved by the Federal Institute for Drugs and Medical Devices and the ethics committees of the participating centers. All patients gave written informed consent.

Competing interests The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as the original work is properly cited. The full text can be accessed via a link to the Creative Commons licence, and indicates if changes were made. This article is protected by copyright. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as the original work is properly cited and a link to the Creative Commons licence is provided. With the written permission of the copyright holder, the material may be used beyond the scope of the licence. In case of a request for permission for any other purpose, the copyright holder must be directly notified. The material is not included in the Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020. https://doi.org/10.3322/caac.21590.
2. Salar A, Sevilla AF, Romagosa V, et al. Distribution and incidence rates of lymphoid neoplasms according to the REAL classification in a single institution: a prospective study of 940 cases. Eur J Haematol. 2009;83(4):231–7. https://doi.org/10.1111/j.1600-0609.1997.tb00982.x.
3. Sant M, Allemani C, Tereau C. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724–34. https://doi.org/10.1182/blood-2011-02-335794.
4. Coiffier B, Lepage E, Brière J, et al. Chop chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002. https://doi.org/10.1056/NEJMoa011795.
5. Pfundenschuh M, Trümper L, Österborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006. https://doi.org/10.1016/S1470-2245(06)70664-7.
6. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993. https://doi.org/10.1056/NEJM199309303291402.
7. Ziepert M, Hasenclever D, Kuhnth E, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010. https://doi.org/10.1200/JCO.2009.26.2493.
8. Rosenberg SA. Validity of the Ann Arbor staging classification for the non-Hodgkin’s lymphomas. Cancer Treat Rep 1977.
9. Poeschel V, Held G, Ziepert M, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019. https://doi.org/10.1016/S0140-6736(19)33008-9.
10. Barrington SF, Mikhael NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014. https://doi.org/10.1200/JCO.2013.53.5229.
11. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014. https://doi.org/10.1200/JCO.2013.54.8800.
12. Adams HJA, Kwee TC, De Keizer R, Fijnheer R, De Klerk JMH, Nievelstein RAJ. FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2014. https://doi.org/10.1007/s00259-013-2623-4.
13. Albanò D, Patti C, La Grutta L, et al. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas. Eur J Radiol. 2016. https://doi.org/10.1016/j.ejrad.2015.12.006.
14. Adams HJA, Kwee TC, Vernooolen MA, et al. Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET. Eur Radiol. 2013. https://doi.org/10.1007/s00330-013-2835-9.
15. Dührsen U, Müller S, Hertenstein B, et al. Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol. 2018. https://doi.org/10.1200/JCO.2017.76.8093.
16. Cerci JJ, Görke T, Fanti S, et al. Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma. J Nucl Med. 2014. https://doi.org/10.2967/jnumed.113.134486.
17. Berthet L, Cochet A, Kanoun S, et al. In newly diagnosed diffuse large-B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med. 2013;54(8):1244–50. https://doi.org/10.2967/jnumed.111.114710.
18. Dwyer AJ. Matchmaking and McNemar in the comparison of diagnostic modalities. Radiology. 1991. https://doi.org/10.1148/radiology.178.2.1987587.
19. Alzahrani M, El-Galaly TC, Hutchings M, et al. The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma: systematic review and meta-analysis. Ann Oncol. 2018. https://doi.org/10.1093/annonc/mdy254.
lymphoma staged with PET/CT: a Danish-Canadian study. Ann Oncol. 2016. https://doi.org/10.1093/annonc/mdw137.

20. Morra E, Lazzarino M, Castello A, et al. Bone marrow and blood involvement by non-Hodgkin’s lymphoma: a study of clinicopathologic correlations and prognostic significance in relationship to the working formulation. Eur J Haematol. 1989. https://doi.org/10.1111/j.1600-0609.1989.tb01469.x.

21. Conlan MG, Bast M, Armitage JO, Weisenburger DD. Bone marrow involvement by non-Hodgkin’s lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. J Clin Oncol. 1990. https://doi.org/10.1200/JCO.1990.8.7.1163.

22. Campbell J, Seymour JF, Matthews J, Wolf M, Stone J, Juneja S. The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol. 2006. https://doi.org/10.1111/j.1600-0609.2006.00644.x.

23. El Karak F, Bou-Orm IR, Ghosn M, et al. PET/CT scanner and bone marrow biopsy in detection of bone marrow involvement in diffuse large B-cell lymphoma. PLoS One. 2017. https://doi.org/10.1371/journal.pone.0170299.

24. Juneja SK, Wolf MM, Cooper IA. Value of bilateral bone marrow biopsy specimens in non-Hodgkin’s lymphoma. J Clin Pathol. 1990. https://doi.org/10.1136/jcp.43.8.630.

25. Khan AB, Barrington SF, Mikhail NG, et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood. 2013. https://doi.org/10.1182/blood-2012-12-473389.

26. Chen-Liang TH, Martin-Santos T, Jerez A, et al. The role of bone marrow biopsy and FDG-PET/CT in identifying bone marrow infiltration in the initial diagnosis of high grade non-Hodgkin B-cell lymphoma and Hodgkin lymphoma. accuracy in a multicenter series of 372 patients. Am J Hematol. 2015. https://doi.org/10.1002/ajh.24044.

27. Weiler-Sagie M, Bushelev O, Epelbaum R, et al. 18F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010. https://doi.org/10.2967/jnumed.109.067892.

28. Schmitz N, Zeynalova S, Nickelsen M, et al. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016. https://doi.org/10.1200/JCO.2015.65.6520.

29. Salem P, Woverson MK, Reimers HJ, Kudva GC. Complications of bone marrow biopsy. Br J Haematol. 2003. https://doi.org/10.1046/j.1365-2141.2003.04328.x.

30. Aoki J, Watanabe H, Shinozaki T, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology. 2001. https://doi.org/10.1148/radiology.219.3.r01ma08774.

31. Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015. https://doi.org/10.1093/annonc/mdv304.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.